8月19日，BioNTech SE盘中上涨23.13%，报114.09美元/股，成交额4.27亿美元。
消息面上，Moderna与默沙东联合研发的mRNA黑色素瘤癌症疫苗三期临床试验取得成功，被市场视为mRNA技术平台在肿瘤治疗领域的历史性突破。BioNTech作为全球领先的mRNA技术平台公司，该试验成功直接验证了其核心技术路线在癌症免疫治疗中的广阔前景，带动公司股价大幅走高。当日生物科技板块全线上涨，Moderna涨超127%，诺瓦瓦克斯医药涨超6%。
BioNTech SE成立于2008年，专注于结合免疫学与mRNA等尖端治疗平台，开发针对癌症和其他疾病的个体化免疫疗法。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.